Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | HTR2C | P28335 | 3/20 | 0.58 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.47 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.47 |
| ▸ | EED | O75530 | 1/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6178879 | 1.00 | MEN1 (0.61) | MEN1KMT2AHTR2CCHRNB2CHRNA7 | |
| SCHEMBL31494212 | 1.00 | MEN1 (0.61) | MEN1KMT2AHTR2CCHRNB2CHRNA7 | |
| SCHEMBL3154247 | 0.95 | HTR2C (0.56) | MEN1KMT2AHTR2CCHRNB2CHRNA7 | |
| SCHEMBL13801054 | 0.94 | HTR2C (0.55) | MEN1KMT2AHTR2CCHRNB2CHRNA7 | |
| SCHEMBL12536768 | 0.91 | HTR2C (0.60) | MEN1KMT2AHTR2CCHRNB2CHRNA7 | |
| SCHEMBL16610729 | 0.83 | MEN1 (0.55) | MEN1KMT2AHTR2CCHRNB2CHRNA7 | |
| SCHEMBL1355770 | 0.83 | KCNH2 (0.52) | MEN1KMT2ACHRNB2CHRNA7CHRNA4 | |
| SCHEMBL1355768 | 0.83 | KCNH2 (0.52) | MEN1KMT2ACHRNB2CHRNA7CHRNA4 | |
| SCHEMBL16409558 | 0.80 | CHRNB2 (0.45) | MEN1KMT2AHTR2CCHRNB2CHRNA7 | |
| SCHEMBL6181098 | 0.80 | MEN1 (0.59) | MEN1KMT2ACHRNB2CHRNA7CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0671388-B1 | (Pyrrolidinyl)phenyl carbamates and intermediate compounds, processes for their preparation and their use as medicaments | HOECHST MARION ROUSSEL INC (US) | 1998-06-10 | — | — | EP | claimed |
| EP-0671388-A1 | (Pyrrolidinyl)phenyl carbamates and intermediate compounds, processes for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1995-09-13 | — | — | EP | claimed |
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LTD (GB) | 2026-04-02 | — | — | US | disclosed |
| EP-4587126-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | Amphista Therapeutics Ltd (GB) | 2025-07-23 | — | — | EP | disclosed |
| EP-4545515-A1 | BCL-2 INHIBITORS | BeiGene Switzerland GmbH (CH) | 2025-04-30 | — | — | EP | disclosed |
| US-20240376104-A1 | Bcl-2 Inhibitors | BEIGENE LTD. (KY) | 2024-11-14 | — | — | US | disclosed |
| US-12077536-B2 | BCL-2 inhibitors | BEIGENE, LTD. (KY) | 2024-09-03 | — | — | US | disclosed |
| US-12016852-B2 | Pyrrolidine glycosidase inhibitors | ASCENEURON SA (CH) | 2024-06-25 | — | — | US | disclosed |
| US-12016852-B2 | Pyrrolidine glycosidase inhibitors | ASCENEURON SA (CH) | 2024-06-25 | — | — | US | disclosed |
| US-11963963-B2 | 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes | SPRINT BIOSCIENCE AB (SE) | 2024-04-23 | — | — | US | disclosed |
| WO-2024057021-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2024-03-21 | — | — | WO | disclosed |
| US-6284785-B1 | HAVING ACTIVITY AS LIGANDS OF METABOTROPIC GLUTAMATE RECEPTORS | HOFFMANN- LA ROCHE INC. | 2001-09-04 | — | — | US | disclosed |
| WO-2000058285-A1 | 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-05 | — | — | WO | disclosed |
| EP-0671388-B1 | (Pyrrolidinyl)phenyl carbamates and intermediate compounds, processes for their preparation and their use as medicaments | HOECHST MARION ROUSSEL INC (US) | 1998-06-10 | — | — | EP | disclosed |
| US-5591856-A | CHEMICAL INTERMEDIATES, TREATMENT OF ALZHEIMER'S DISEASE | HOECHST ROUSSEL PHARMACEUTICALS INC. (US) | 1997-01-07 | — | — | US | disclosed |
| US-5554750-A | TO RELIEVE MEMORY DYSFUNCTIONS; TREATMENT OF ALZHEMER*S | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1996-09-10 | — | — | US | disclosed |
| EP-0671388-A1 | (Pyrrolidinyl)phenyl carbamates and intermediate compounds, processes for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1995-09-13 | — | — | EP | disclosed |
| US-5405845-A | Administering to relieve memory dysfunction; treatment of Alzheimer's disease | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1995-04-11 | — | — | US | disclosed |
| US-5338739-A | Memory dysfunction relieving compounds | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1994-08-16 | — | — | US | disclosed |
| US-4957927-A | (Diarylmethoxy alkyl)-1-pyrrolidines and piperidines having cardiovascular activity | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1990-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12077536-B2 | BCL-2 inhibitors | BCL2, BCL2L1, BCL2L2 | MEN1 3803/4885KMT2A 2464/4885HTR2C 3764/4885 |
| US-12016852-B2 | Pyrrolidine glycosidase inhibitors | PREP, GAA, DNPEP | MEN1 4229/4885KMT2A 2017/4885HTR2C 4656/4885 |
| US-11963963-B2 | 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes | CDK6, IL6, CDK4 | MEN1 198/4885KMT2A 1304/4885HTR2C 1411/4885 |
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | BCL9L, RBBP9, BRD9 | MEN1 3261/4885KMT2A 4018/4885HTR2C 3172/4885 |
| US-20240376104-A1 | Bcl-2 Inhibitors | BCL2, BCL2L1, BCL2L2 | MEN1 3803/4885KMT2A 2464/4885HTR2C 3764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.